TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_93
Abstract: FLIPI risk category progressed in 60.5% (N = 69), which was associated with inferior outcome compared with pts with stable FLIPI (39.5%, N = 45), p = 0.006 (Figure 1C). In contrast, annual FLIPI risk… read more here.
Keywords: risk; diagnosis 2nd; treatment; time diagnosis ... See more keywords
First external validation of the FLIPI-L score in a single-centre series of patients with follicular lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Hematological oncology"
DOI: 10.1002/hon.2953
Abstract: The FLIPI-L has recently been proposed as a novel prognostic index in follicular lymphoma (FL), combining FLIPI and the presence of lymphopenia. In our single-centre validation in 381 FL patients, lymphopenia was less frequent than… read more here.
Keywords: single centre; follicular lymphoma; flipi; validation ... See more keywords
Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130208
Abstract: Introduction : We have previously shown that a clinicogenetic risk model called the m7- Follicular Lymphoma (FL) International Prognostic Index (m7-FLIPI), which includes the mutation status of 7 genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP,… read more here.
Keywords: status; research; research funding; flipi ... See more keywords